Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relenza Growth Will Rely On Prophylaxis Use; Flovent Flies In U.S., Up 55%

Executive Summary

A Relenza prophylaxis indication is key to the future growth of the inhaled neuraminidase inhibitor, Glaxo Wellcome Chairman Richard Sykes said July 27 at a half-year results meeting in London.
Advertisement

Related Content

Roche Xenical Patient Compliance Could Increase With New DTC Campaign
Roche Xenical Patient Compliance Could Increase With New DTC Campaign
Glaxo's Lotronex Risk-Management Program Emphasizes Appropriate Use
Relenza Prophylaxis Indication Withdrawn In EU; Pediatric Use Cleared In U.S.
Relenza Prophylaxis Indication Withdrawn In EU; Pediatric Use Cleared In U.S.
Relenza Studies In High-Risk Populations Might Show More Efficacy - Cmte.
Advertisement
UsernamePublicRestriction

Register

PS036440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel